Payment overview · 2025
General Payments
$135.10
3 reported records · 2 companies
Healthcare provider profile · identity verified
Ute E Gallert, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WATERLOO, NY · NPI 1417204355
Verified facts
What the public records show
CMS Open Payments records show Ute E Gallert, FNP received $135.10 in general payments during 2025 across 3 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 75.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $101.95 | 75.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.15 | 24.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $135.10 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $101.95 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 676 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 66 |
| Omeprazole | Omeprazole | 348 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 72 |
| Metformin Hcl | Metformin Hcl | 250 | 52 |
| Losartan Potassium | Losartan Potassium | 239 | 50 |
| Lisinopril | Lisinopril | 237 | 57 |
| Gabapentin | Gabapentin | 198 | 38 |
| Montelukast Sodium | Montelukast Sodium | 187 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 185 | 30 |
| Furosemide | Furosemide | 180 | 36 |
| Trazodone Hcl | Trazodone Hcl | 174 | 27 |
| Famotidine | Famotidine | 160 | 26 |
| Bupropion Xl | Bupropion Hcl | 153 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 35 |
| Trulicity | Dulaglutide | 136 | 21 |
| Buspirone Hcl | Buspirone Hcl | 119 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 19 |
| Ibuprofen | Ibuprofen | 108 | 29 |
| Sertraline Hcl | Sertraline Hcl | 108 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 21 |
| Atenolol | Atenolol | 97 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 16 |
| Potassium Chloride | Potassium Chloride | 88 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 13 |
| Metformin Hcl Er | Metformin Hcl | 73 | 13 |
| Ozempic | Semaglutide | 71 | 11 |
| Alendronate Sodium | Alendronate Sodium | 64 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 57 | suppressed |
| Eliquis | Apixaban | 55 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 54 | 11 |
| Chlorthalidone | Chlorthalidone | 53 | 12 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Simvastatin | Simvastatin | 52 | 11 |
| Topiramate | Topiramate | 52 | suppressed |
| Sucralfate | Sucralfate | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Baclofen | Baclofen | 46 | 13 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | 14 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Klor-Con M10 | Potassium Chloride | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Prednisone | Prednisone | 28 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $135.10 · 3 records | Bayer Healthcare Pharmaceuticals Inc. | Kerendia, MAVYRET, QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error